prioriti review week februari
may miss past week
realli valu time case miss anyth weve provid quick
summari major event past week key event watch
upcom week also link research model applic
highlight frequent inbound question debat topic come
investor minut read pleas let us know
prevail tecfidera ipr ptab upheld patent
maintain patent protect remov major overhang stock mylan
said would appeal two on-going tecfidera h-w trial expect mid-year
tecfidera ip notch anoth win though growth prospect still link adu
roche/ptc report phase data sunfish part detail data
present investor event intern scientif congress sma show
improv motor function overal independ vs placebo risdiplam
confirm good type data well-posit challeng spinraza
unit distinct trial meet primari endpoint sclc phase
evalu unituxin potenti therapi meet os endpoint
distinct miss unexpect broader growth concern remain
biomarin cfo announc departur compani compani cfo
spiegelman announc plan depart brian mueller cao assum role
perman candid chosen thought cfo departur
merck spin slower-growth asset new compani would includ women
health legaci brand biosimilar drug leav merck focu effort higher-
growth franchis core i/o vaccin anim health
ema accept file gsk belantamab mafodotin r/r multipl myeloma
submiss treatment patient r/r multipl myeloma whose prior
therapi includ immunomodulatori agent proteasom inhibitor
antibodi base pivot
merck recarbrio grant prioriti review habp/vabp accept
base result phase restore-imi trial evalu recarbrio imipenem
cilastatin relebactam adult habp/vabp pdufa date june
merck belsomra receiv fda approv label expans approv
extend belsomra suvorex label includ treatment insomnia patient
mild-to-moder alzheim diseas
unit prevail initi anti-trust proceed district court unseal
decis declin sandoz/ raregen preliminari injunct unit smith
regard access remodulin pump system trial yet schedul
pleas see top incom question proprietari research past week
upcom event start page
bofa secur seek busi issuer cover research report
result investor awar firm may conflict interest could
affect object report investor consid report singl
factor make invest decis
refer import disclosur page analyst certif page price object
basis/risk page
ptab patent trial appeal board
r/r relaps refractori
investor ask follow topic phone call email in-
thought merck announc spin-off like long-term pictur
remainco post spin recogn done
posit strength given transform impact keytruda
busi said financi optic remainco next
month revenue/ep growth margin look quit differ merck
investor becom accustom toand think uninspir growth
profil could weigh share time look past
think signific valu creation post-spin take-away
discuss manag seem sens
urgenc improv growth profil nearer-term takeaway
manag lunch
take ipr-rel strength share share saw
signific strength week ptab upheld patent
maintain tecfidera us patent protect given case
major concern among investor given tecfidera contribut
us sale total revenu recogn share upsid
inevit given posit outcom said view
ad market cap overreact news think biogen
growth prospect continu show uncertain trajectori tecfidera
ip notch anoth win though growth prospect still link adu
takeaway alexion complement analysi call alexion
offens defens commerci strategi core complement
busi continu weather competit
impress commerci execut investor view concentr risk
franchis pipelin progress competitor inevit
launch soliri biosimilar justif low multipl view
guidanc fail inspir ep growth see
continu neg competit scenario play
street overblown analysi reaffirm bullish alexion posit given
advantag dose contribut patient sticki support
scientif literatur suggest rare diseas patient switch
particularli generics/biosimilar difficult fear inde
kol emphas patient conveni eas complianc critic
factor choos orphan diseas treatment fulli expect
ultomiri remain standard care four current soliris-
domin indic pnh ahu gmg nmosd limit potenti
eros competitor us biopharmaceut landscap analysi
show durabl alexion complement franchis
proprietari research past week
us biopharmaceut landscap analysi show durabl alexion
takeaway manag lunch
risdiplam confirm good type data well-posit challeng
tecfidera ip notch anoth win though growth prospect still link
thought cfo departur
biktarvi failur underscor efficaci strength gilead hiv
distinct miss unexpect broader growth concern remain
withdraw lung file eu us file pdufa intact
coverag earn
thought call
initi thought earn
sni earn read-through coverag univers
thought call
initi thought earn
thought call
initi thought earn
gsk earn read-through coverag univers
thought call
initi thought earn
thought call
initi thought earn
thought call
initi thought earn
thought call
initi thought earn
thought call
initi thought earn
thought call
initi thought earn
thought call
initi thought result
roch earn read-through coverag univers
nv earn read-through coverag univers
thought follow call
initi thought earn
earn read-through coverag univers
watch week ahead
clinic trial read-out regulatori event expect near-term
jan phase top-line data heart failur victoria
earli phase data pnh/ahu sc formul
earli phase top-line data tnbc
earli bla file alzheim diseas
earli phase top-line data rcc
march pdufa date multipl sclerosi
asbmt american societi blood marrow transplant houston tx
icid intern congress infecti diseas kuala lumpur malaysia
aapm american academi pain medicin nation harbor md februari
actrim america committe treatment research multipl
price object alexion base npv analysi
forecast sale approv product soliri ultomiri strensiq
kanuma well probabl adjust assum
wacc line peer compani similar size risk differ
termin valu asset depend specif characterist patent
protect given assumpt estim valu soliri
ultomiri strensiq kanuma net
cash round po
downsid risk success competitor trial price pressur less
expens treatment altern clinic trial failur
price object base sum-of-th part npv analysi forecast sale
key product use wacc vari termin growth rate
asset base characterist patent life
assumpt valu entir ms franchis spinraza
collabor revenu biosimilar pipelin net
cash net po
upsid risk po better expect sale tecfidera less eros
avonex plegridi tysabri anticip vumer meaning captur
market share strong durabl spinraza success number early-stag
pipelin program result acceler approv develop
downsid risk greater expect moder ms sale avonex plegridi
tysabri due increas competit rapid eros spinraza market share
sma limit success pipelin mani product fail advanc
approv narrow indic smaller patient popul
price object po base combin intrins valu remainco
newco valu remainco base
blend averag price-to-earnings multipl appli ep reflect continu
strength merck core growth franchis risk-adjust dcf wacc
termin growth rate valu newco base assum ev/ebitda
first full year repres discount vs peer reflect slow growth
risk po impress competitor readout result key i/o indic
nsclc rcc rapid declin across diabet franchis
expect neg outcom compani later-stag asset on-going
develop pressur headlin risk face sector includ drug price
reform spin-off take place
geoff meacham herebi certifi view express research report
accur reflect person view subject secur issuer also
certifi part compens directli indirectli relat
specif recommend view express research report
